Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Functional characterization of CHEK2 variants in a Saccharomyces cerevisiae system

A. Delimitsou, F. Fostira, D. Kalfakakou, P. Apostolou, I. Konstantopoulou, C. Kroupis, AG. Papavassiliou, Z. Kleibl, E. Stratikos, GE. Voutsinas, D. Yannoukakos,

. 2019 ; 40 (5) : 631-648. [pub] 20190309

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc20006542

Grantová podpora
A.G. Leventis Foundation - International
IKY_Greek State Scholarships Foundation - International
P. BROCA research program ARISTEIA - International
ARISTEIA 39 research program ARISTEIA - International
European Union (European Social Fund, ESF) - International
Greek national funds through the Operational Program - International
MIS 5002514 Target Identification and Development of Novel Approaches for Health and Environmental Applications - International
NSRF 2014-2020 Competitiveness, Entrepreneurship and Innovation - International
Greece and the European Union (European Regional Development Fund) - International

Genetic testing for cancer predisposition leads to the identification of a number of variants with uncertain significance. To some extent, variants of BRCA1/2 have been classified, in contrast to variants of other genes. CHEK2 is a typical example, in which a large number of variants of unknown clinical significance were identified and still remained unclassified. Herein, the CHEK2 variant assessment was performed through an in vivo, yeast-based, functional assay. In total, 120 germline CHEK2 missense variants, distributed along the protein sequence, and two large in-frame deletions were tested, originating from genetic test results in breast cancer families, or selected from the ClinVar database. Of these, 32 missense and two in-frame deletions behaved as non-functional, 73 as functional, and 15 as semi-functional, after comparing growth rates of each strain with positive and negative controls. The majority of non-functional variants were localized in the CHK2 kinase and forkhead-associated domains. In vivo results from the non-functional variants were in agreement with in silico predictions, and, where available, with strong breast cancer family history, to a great extent. The results of the largest, to date, yeast-based assay, evaluating CHEK2 variants, can complement and assist in the classification of rare CHEK2 variants with unclear clinical significance.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20006542
003      
CZ-PrNML
005      
20200521090415.0
007      
ta
008      
200511s2019 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1002/humu.23728 $2 doi
035    __
$a (PubMed)30851065
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Delimitsou, Angeliki $u Molecular Diagnostics Laboratory, INRaSTES, National Center for Scientific Research "Demokritos", Athens, Greece. Laboratory of Environmental Mutagenesis and Carcinogenesis, Institute of Biosciences and Applications, National Centre for Scientific Research "Demokritos", Athens, Greece.
245    10
$a Functional characterization of CHEK2 variants in a Saccharomyces cerevisiae system / $c A. Delimitsou, F. Fostira, D. Kalfakakou, P. Apostolou, I. Konstantopoulou, C. Kroupis, AG. Papavassiliou, Z. Kleibl, E. Stratikos, GE. Voutsinas, D. Yannoukakos,
520    9_
$a Genetic testing for cancer predisposition leads to the identification of a number of variants with uncertain significance. To some extent, variants of BRCA1/2 have been classified, in contrast to variants of other genes. CHEK2 is a typical example, in which a large number of variants of unknown clinical significance were identified and still remained unclassified. Herein, the CHEK2 variant assessment was performed through an in vivo, yeast-based, functional assay. In total, 120 germline CHEK2 missense variants, distributed along the protein sequence, and two large in-frame deletions were tested, originating from genetic test results in breast cancer families, or selected from the ClinVar database. Of these, 32 missense and two in-frame deletions behaved as non-functional, 73 as functional, and 15 as semi-functional, after comparing growth rates of each strain with positive and negative controls. The majority of non-functional variants were localized in the CHK2 kinase and forkhead-associated domains. In vivo results from the non-functional variants were in agreement with in silico predictions, and, where available, with strong breast cancer family history, to a great extent. The results of the largest, to date, yeast-based assay, evaluating CHEK2 variants, can complement and assist in the classification of rare CHEK2 variants with unclear clinical significance.
650    _2
$a alely $7 D000483
650    _2
$a substituce aminokyselin $7 D019943
650    _2
$a checkpoint kinasa 2 $x genetika $x metabolismus $7 D064447
650    _2
$a výpočetní biologie $x metody $7 D019295
650    _2
$a frekvence genu $7 D005787
650    _2
$a genetické asociační studie $7 D056726
650    _2
$a genetická predispozice k nemoci $7 D020022
650    _2
$a lidé $7 D006801
650    _2
$a molekulární modely $7 D008958
650    12
$a mutace $7 D009154
650    _2
$a rodokmen $7 D010375
650    _2
$a konformace proteinů $7 D011487
650    _2
$a Saccharomyces cerevisiae $x genetika $x metabolismus $7 D012441
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Fostira, Florentia $u Molecular Diagnostics Laboratory, INRaSTES, National Center for Scientific Research "Demokritos", Athens, Greece.
700    1_
$a Kalfakakou, Despoina $u Molecular Diagnostics Laboratory, INRaSTES, National Center for Scientific Research "Demokritos", Athens, Greece.
700    1_
$a Apostolou, Paraskevi $u Molecular Diagnostics Laboratory, INRaSTES, National Center for Scientific Research "Demokritos", Athens, Greece.
700    1_
$a Konstantopoulou, Irene $u Molecular Diagnostics Laboratory, INRaSTES, National Center for Scientific Research "Demokritos", Athens, Greece.
700    1_
$a Kroupis, Christos $u Department of Clinical Biochemistry, "Attikon" University General Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
700    1_
$a Papavassiliou, Athanasios G $u Department of Biological Chemistry, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
700    1_
$a Kleibl, Zdenek $u Institute of Biochemistry and Experimental Oncology, First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic.
700    1_
$a Stratikos, Efstratios $u Protein Chemistry Laboratory, INRaSTES, National Center for Scientific Research "Demokritos", Athens, Greece.
700    1_
$a Voutsinas, Gerassimos E $u Laboratory of Environmental Mutagenesis and Carcinogenesis, Institute of Biosciences and Applications, National Centre for Scientific Research "Demokritos", Athens, Greece.
700    1_
$a Yannoukakos, Drakoulis $u Molecular Diagnostics Laboratory, INRaSTES, National Center for Scientific Research "Demokritos", Athens, Greece.
773    0_
$w MED00002078 $t Human mutation $x 1098-1004 $g Roč. 40, č. 5 (2019), s. 631-648
856    41
$u https://pubmed.ncbi.nlm.nih.gov/30851065 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20200511 $b ABA008
991    __
$a 20200521090412 $b ABA008
999    __
$a ok $b bmc $g 1525400 $s 1096598
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 40 $c 5 $d 631-648 $e 20190309 $i 1098-1004 $m Human mutation $n Hum Mutat $x MED00002078
GRA    __
$p A.G. Leventis Foundation $2 International
GRA    __
$p IKY_Greek State Scholarships Foundation $2 International
GRA    __
$a P. BROCA $p research program ARISTEIA $2 International
GRA    __
$a ARISTEIA 39 $p research program ARISTEIA $2 International
GRA    __
$p European Union (European Social Fund, ESF) $2 International
GRA    __
$p Greek national funds through the Operational Program $2 International
GRA    __
$a MIS 5002514 $p Target Identification and Development of Novel Approaches for Health and Environmental Applications $2 International
GRA    __
$a NSRF 2014-2020 $p Competitiveness, Entrepreneurship and Innovation $2 International
GRA    __
$p Greece and the European Union (European Regional Development Fund) $2 International
LZP    __
$a Pubmed-20200511

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...